High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study

Introduction: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). Antiangiogenic therapy may enhance CNS drug delivery and EGFR-TKI efficacy​. We e...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yin Pan, Meichen Li, Mingjie Yu, Jing Chen, Hui Yu, Kaijing Liu, Likun Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-11-01
Colecção:	Translational Oncology
Assuntos:	Furmonertinib EGFR-TKI resistance Brain Metastases EGFR mutation
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1936523325002311
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!